Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01).

[1]  R. Sylvester,et al.  Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  G. Sonpavde,et al.  A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. , 2011, The Lancet. Oncology.

[3]  J. Maroto,et al.  Randomized phase II/III trial comparing gemcitabine/carboplatin (GC) and methotrexate/carboplatin/vinblastine (M-CAVI) in patients (pts) with advanced urothelial cancer (UC) unfit for cisplatin-based chemotherapy (CHT): Phase III results of EORTC study 30986. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Sylvester,et al.  Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Amadori,et al.  Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. , 2007, European urology.

[6]  R. Crevoisier,et al.  A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  L. Collette,et al.  Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. , 2006, European journal of cancer.

[8]  Sergio Ricci,et al.  Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Mencoboni,et al.  Single-Agent Gemcitabine in Previously Untreated Elderly Patients with Advanced Bladder Carcinoma: Response to Treatment and Correlation with the Comprehensive Geriatric , 2004, Oncology.

[10]  J. Carles,et al.  Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Hammel,et al.  Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  W. Curran,et al.  Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. , 2000, International journal of radiation oncology, biology, physics.

[14]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[15]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[16]  M. Mazumdar,et al.  Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  E. Raymond,et al.  Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines , 1999, Cancer Chemotherapy and Pharmacology.

[18]  I. Tannock,et al.  Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Ribas,et al.  Carboplatin‐based versus cisplatin‐based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma , 1997, Cancer.

[20]  I. Tannock,et al.  Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Mondillo,et al.  Comparison between a cisplatin‐containing regimen and a carboplatin‐containing regimen for recurrent or metastatic bladder cancer patients: A randomized phase II study , 1996, Cancer.

[22]  C. Logothetis,et al.  A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.